Announcement
Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the Article
Posted in the last 24 hours
Fresh from the desks
redistricting
Missouri's Secretary of State Must Answer to Two Courts at Once
The state Supreme Court has opened a contempt probe into Denny Hoskins over the congressional map fight, while a federal judge keeps ordering him to use that same map.
tax privacy
A Court Counted 42,695 Unlawful Disclosures in the IRS-ICE Data Pipeline
The D.C. Circuit has upheld an injunction against the IRS sharing taxpayer addresses with immigration authorities, and the opinion reads like an audit of a data handoff gone wrong.
bank supervision
Bank Regulators Just Defined What Unsafe and Unsound Means
The FDIC and OCC have finalized the first regulatory definition of an "unsafe or unsound practice," and it deliberately leaves reputation risk out.
abortion policy
One Louisiana Case Could Decide How Abortion Pills Reach Every State
The Fifth Circuit heard arguments Tuesday in Louisiana v. FDA, a challenge that seeks to end telehealth prescribing and mailed mifepristone nationwide.
AI policy
Washington Accuses Six Chinese AI Firms of Industrial-Scale Copying
A joint FBI, NSA and CISA advisory names DeepSeek, Alibaba and four others, alleging billions of tokens were extracted from American frontier models.
immigration
Imran Ahmed's Deportation Fight Now Rests on Five Business Days
A federal judge dismissed the British activist's lawsuit challenging his potential deportation, while keeping a temporary restraining order alive long enough for an appeal.
rare disease
The $12 Billion Muscle Drug Missed Its Big Test
Novartis' del-desiran failed its Phase III endpoint in myotonic dystrophy type 1, a setback for the centerpiece of the Avidity Biosciences acquisition.
lung cancer
The First Survival Win for a BiTE Drug Arrives in Small Cell Lung Cancer
AstraZeneca and Amgen's DeLLphi-305 trial showed Imfinzi plus Imdelltra improved overall survival in extensive-stage small cell lung cancer.
angioedema
An Oral Drug Cut HAE Attacks by 83 Percent in a Pivotal Trial
Pharvaris' deucrictibant extended-release tablets met the primary endpoint of the CHAPTER-3 study, including in the HAE subgroup with no dedicated prophylactic option.
B2B Research
Most Popular Research Articles
Intent Data
Intent Data Providers For B2B
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
Knowledge Management
Knowledge Management Solutions
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
MDR
Managed Detection And Response Services
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
MDR Europe
Managed Detection And Response Services In Europe
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Manufacturing Tech
Manufacturing Technology Services
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Market Intelligence
Market And Competitive Intelligence Platforms
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Open Banking
Open Banking Intermediaries
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Change Management
Organizational Change Management Services
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
PLM
Product Lifecycle Management Platforms For Discrete Manufacturers
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Announcements
News from Mavengity
Announcement
James T. Joins Mavengity as a Medical Writer
With James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article
Browse by topic
Where would you like to start?
Every article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Insurance
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceMortgage
Rates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgagePersonal Finance
Budgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceLegal
Contracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealthcare & Medical
Health coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareResearch
Gartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse Research
Why Mavengity
Editorial standards you can check
Independently researched
We start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
Plain-English explanations
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
Straight, not slanted
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Written for readers, not lenders
Mavengity is reader-supported and editorially independent from the products we cover.